CDXS

Codexis Inc

CDXS, USA

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

https://www.codexis.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
CDXS
stock
CDXS

Opaleye management sells Codexis (CDXS) shares for $1.87 million Investing.com

Read more →
CDXS
stock
CDXS

Opaleye management sells Codexis (CDXS) shares worth $877,846 Investing.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$6.5833

Analyst Picks

Strong Buy

4

Buy

1

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

3.91

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-50.89 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-15.82 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-91.68 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

2.22

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 94.14% of the total shares of Codexis Inc

1.

Opaleye Management Inc

(13.9585%)

since

2025/06/30

2.

Casdin Capital, LLC

(7.9763%)

since

2025/06/30

3.

BlackRock Inc

(7.9053%)

since

2025/06/30

4.

FMR Inc

(5.1074%)

since

2025/06/30

5.

Vanguard Group Inc

(5.084%)

since

2025/06/30

6.

Aberdeen Group PLC

(4.6539%)

since

2025/06/30

7.

Nantahala Capital Management, LLC

(4.4652%)

since

2025/06/30

8.

Telemark Asset Management, LLC

(4.4313%)

since

2025/06/30

9.

Ameriprise Financial Inc

(2.8258%)

since

2025/06/30

10.

abrdn Healthcare Investors

(2.7748%)

since

2025/08/31

11.

Vanguard Total Stock Mkt Idx Inv

(2.6293%)

since

2025/07/31

12.

iShares Russell 2000 ETF

(2.2087%)

since

2025/08/31

13.

Geode Capital Management, LLC

(2.1911%)

since

2025/06/30

14.

Pier Capital, LLC

(2.1217%)

since

2025/06/30

15.

Columbia Small Cap Value Discv A

(1.8812%)

since

2025/07/31

16.

Baillie Gifford & Co Limited.

(1.8674%)

since

2025/06/30

17.

Columbia Small Cap Value Discovery Fund

(1.8294%)

since

2025/06/30

18.

State Street Corp

(1.7873%)

since

2025/06/30

19.

abrdn Life Sciences Investors

(1.7585%)

since

2025/08/31

20.

Jacobs Levy Equity Management, Inc.

(1.3052%)

since

2025/06/30

21.

Fidelity VIP Growth Initial

(1.264%)

since

2025/07/31

22.

Fidelity Advisor Equity Growth I

(1.2439%)

since

2025/07/31

23.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9826%)

since

2025/07/31

24.

Federated Hermes Inc

(0.9669%)

since

2025/06/30

25.

Fidelity Small Cap Index

(0.9033%)

since

2025/06/30

26.

Renaissance Technologies Corp

(0.8369%)

since

2025/06/30

27.

Pier Capital Small Cap Growth Equity

(0.7997%)

since

2025/06/30

28.

SEB Nordamerikafond Småbolag

(0.7839%)

since

2025/07/31

29.

Prescott Group Capital Management LLC

(0.7761%)

since

2025/06/30

30.

Baillie Gifford Global Discovery A Acc

(0.7533%)

since

2025/07/31

31.

Northern Trust Corp

(0.7302%)

since

2025/06/30

32.

iShares Russell 2000 Growth ETF

(0.6794%)

since

2025/08/31

33.

Fidelity Growth Discovery

(0.6414%)

since

2025/07/31

34.

Dimensional Fund Advisors, Inc.

(0.6338%)

since

2025/06/30

35.

BlackRock Advantage Small Cap Core Instl

(0.5841%)

since

2025/07/31

36.

Private Advisor Group, LLC

(0.5793%)

since

2025/06/30

37.

Putnam Small Cap Value A

(0.571%)

since

2025/07/31

38.

Federated Hermes MDT Small Cap Core IS

(0.5574%)

since

2025/06/30

39.

Federated Hermes MDT SCC Institutional

(0.5574%)

since

2025/06/30

40.

iShares Biotechnology ETF

(0.5296%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

No earnings data available.

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

Codexis Inc (CDXS) Stock Details & Analysis - Finnton | Finnton